Kymera Therapeutics Inc
KYMR
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.25B
Close$
$0.02
100% downside
Current Fair Value
100% downsideOvervalued by 100% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.25 Billion |
|---|---|
| Enterprise Value | $9.20 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.69 |
| Beta | 1.98 |
| Outstanding Shares | 98,177,158 |
Return
| Return on Equity | -19.85% |
|---|---|
| Return on Assets | -18.21% |
| Return on Invested Capital | -20.45% |
Valuation & Multiples
| P/E Ratio | -34.58 |
|---|---|
| PEG | 172.02 |
| Price to Sales | 106.83 |
| Price to Book Ratio | 7.12 |
| Enterprise Value to Revenue | 87.66 |
| Enterprise Value to EBIT | -28.66 |
| Enterprise Value to Net Income | -31 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.71
Average shareholder expectationRevenue Estimate
$32.78 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-1.27
Average shareholder expectationRevenue Estimate
$3.10 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 75.52% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 100.01% |
|---|---|
| Total Invested | $108,995▼ 100.00% |
| Investors Holding | 4▼ 289.00% |
ESG Score
No data
About Kymera Therapeutics Inc
75 employeesKymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted...